SCHEMBL16699323

SCHEMBL16699323

NC(=O)N1CCn2nc(-c3ccc(F)c(Cl)c3)c(C(=O)NC3CNC3)c2C1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 20/20 0.60
CSNK1D P48730 14/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16711178 0.88 CSNK1E (0.63) CSNK1ECSNK1D
SCHEMBL18171133 0.83 CSNK1E (0.64) CSNK1ECSNK1D
SCHEMBL16700043 0.81 CSNK1E (0.57) CSNK1ECSNK1D
SCHEMBL16700447 0.81 CSNK1E (0.53) CSNK1ECSNK1D
SCHEMBL18171198 0.81 CSNK1E (0.61) CSNK1ECSNK1D
SCHEMBL16718786 0.80 CSNK1E (0.53) CSNK1ECSNK1D
SCHEMBL16698479 0.80 CSNK1E (0.52) CSNK1ECSNK1D
SCHEMBL18171243 0.79 CSNK1E (0.55) CSNK1ECSNK1D
SCHEMBL16699702 0.78 CSNK1E (0.51) CSNK1ECSNK1D
SCHEMBL16699614 0.78 CSNK1E (0.62) CSNK1ECSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160122358-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-05 US disclosed
US-9273058-B2 Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-01 US disclosed
US-20150133428-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122358-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 CSNK1E 1/4885CSNK1D 7/4885
US-20150133428-A1 NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 CSNK1E 1/4885CSNK1D 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.